Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC by Eric Tu, Kelly McGlinchey, Jixin Wang, Philip Martin, Steven L.K. Ching, Nicolas Floc’h, James Kurasawa, Jacqueline H. Starrett, Yelena Lazdun, Leslie Wetzel, Barrett Nuttall, Felicia S.L. Ng, Karen T. Coffman, Paul D. Smith, Katerina Politi, Zachary A. Cooper, Katie Streicher

Get full text

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells by Steven W. Criscione, Matthew J. Martin, Derek B. Oien, Aparna Gorthi, Ricardo J. Miragaia, Jingwen Zhang, Huawei Chen, Daniel L. Karl, Kerrin Mendler, Aleksandra Markovets, Sladjana Gagrica, Oona Delpuech, Jonathan R. Dry, Michael Grondine, Maureen M. Hattersley, Jelena Urosevic, Nicolas Floc’h, Lisa Drew, Yi Yao, Paul D. Smith

Get full text

BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors by Jordi Bertran-Alamillo, Ana Giménez-Capitán, Ruth Román, Sara Talbot, Rebecca Whiteley, Nicolas Floc’h, Elizabeth Martínez-Pérez, Matthew J. Martin, Paul D. Smith, Ivana Sullivan, Mikkel G. Terp, Jamal Saeh, Cristina Marino-Buslje, Giulia Fabbri, Grace Guo, Man Xu, Cristian Tornador, Andrés Aguilar-Hernández, Noemí Reguart, Henrik J. Ditzel, Alejandro Martínez-Bueno, Núria Nabau-Moretó, Amaya Gascó, Rafael Rosell, J. Elizabeth Pease, Urszula M. Polanska, Jon Travers, Jelena Urosevic, Miguel A. Molina-Vila

Get full text